Verrica Pharma climbs after EU nod clears path for skin drug filing

Verrica Pharmaceuticals

20/10/2025 21:24

** Shares of drug developer Verrica Pharmaceuticals VRCA.O rise 17% to $5.17 in extended trading

** Co says it received positive feedback from the European Medicines Agency for its skin disease treatment, Ycanth

** Co plans to submit a regulatory filing for the drug in the European Union as early as the fourth quarter of 2026

** The drug, already approved in the U.S. and Japan to treat molluscum contagiosum, a common viral skin infection that spreads through direct contact and mostly affects children

** Stock down 36% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))